BLLN
Bearish signalScored 2026-10-21 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
BillionToOne, Inc.
- Nom
- BillionToOne, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $5.1B
- Employés
- 713
- PDG
- Oguzhan Atay
- Site web
- https://www.billiontoone.com
- Marché
- FLGTGHGRALMYGNNEONTRA
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 101 665 titres (~10 302 510,52 $ US)
- Insiders
- Atay OguzhanTsao David
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$9,303,108
Avg sell (VWAP, 90d window) $115.06 vs last close $104.67 (-9.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$9,303,108 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $57,751,960/day · 20d vol
- Last synced
-
2026-10-21 21:10:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Atay Oguzhan | Sell · S · 10b5-1 | 133 | $102.78 | $13,669 | Form 4 |
| 2026-10-14 | Atay Oguzhan | Sell · S · 10b5-1 | 100 | $99.00 | $9,900 | Form 4 |
| 2026-10-12 | Atay Oguzhan | Sell · S · 10b5-1 | 1,521 | $96.39 | $146,613 | Form 4 |
| 2026-10-05 | Tsao David | Sell · S · 10b5-1 | 100 | $110.09 | $11,009 | Form 4 |
| 2026-10-05 | ten Bosch John Roderick | Sell · S · 10b5-1 | 1,417 | $105.15 | $148,998 | Form 4 |
| 2026-09-28 | Atay Oguzhan | Sell · S · 10b5-1 | 8,333 | $120.64 | $1,005,293 | Form 4 |
| 2026-09-24 | Tsao David | Sell · S · 10b5-1 | 3,333 | $125.00 | $416,625 | Form 4 |
| 2026-09-24 | ten Bosch John Roderick | Sell · S · 10b5-1 | 1,416 | $120.00 | $169,920 | Form 4 |
| 2026-09-21 | ten Bosch John Roderick | Sell · S · 10b5-1 | 1,416 | $106.61 | $150,960 | Form 4 |
| 2026-09-17 | Lynch Thomas P. | Sell · S · 10b5-1 | 5,840 | $110.29 | $644,112 | Form 4 |
| 2026-09-14 | Atay Oguzhan | Sell · S · 10b5-1 | 3,143 | $101.49 | $318,989 | Form 4 |
| 2026-09-09 | Tsao David | Sell · S · 10b5-1 | 10,000 | $100.00 | $1,000,000 | Form 4 |
| 2026-09-09 | ten Bosch John Roderick | Sell · S · 10b5-1 | 1,416 | $97.54 | $138,117 | Form 4 |
| 2026-09-08 | Lynch Thomas P. | Sell · S · 10b5-1 | 232 | $100.92 | $23,414 | Form 4 |
| 2026-08-25 | Tsao David | Sell · S · 10b5-1 | 10,000 | $100.00 | $1,000,000 | Form 4 |
| 2026-08-25 | ten Bosch John Roderick | Sell · S · 10b5-1 | 1,417 | $100.00 | $141,700 | Form 4 |
| 2026-08-10 | Tsao David | Sell · S · 10b5-1 | 10,000 | $92.86 | $928,600 | Form 4 |
| 2026-08-10 | ten Bosch John Roderick | Sell · S · 10b5-1 | 1,417 | $92.86 | $131,583 | Form 4 |
| 2026-08-05 | Atay Oguzhan | Sell · S · 10b5-1 | 15,539 | $150.03 | $2,331,352 | Form 4 |
| 2026-08-03 | Atay Oguzhan | Sell · S · 10b5-1 | 82 | $139.20 | $11,415 | Form 4 |
| 2026-07-31 | Sakakibara Shan Riku | Sell · S · 10b5-1 | 4,000 | $140.21 | $560,840 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-21 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
BLLN exhibits exceptional liquidity (current ratio 11.69) and a genuine 2025 profitability turnaround, but these strong fundamentals are severely undermined by a near-zero catalyst score driven by aggressive, repeated…
The first sentence of the analysis written for BLLN on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $9.3M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $9.3M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 11.69 · operating margin 5.3%
Suggested stop 85.56, nearest stored support minus 0.5 ATR(18.2% under the last close). Reward/risk to the next stored resistance is 0.28. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 Billiontoone (NASDAQ:BLLN) CEO Sells $516,184.50 in Stock Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) CEO Oguzhan Atay sold 5,150 shares of the business''s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $100.23, for a total value of $516,184.50. Following the completion of the sale, the chief executive officer directly owned 3,183 shares of
- 2026-10-14 BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
- 2026-10-12 BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.
- 2026-10-07 BillionToOne''s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response
- 2026-10-02 Billiontoone (NASDAQ:BLLN) Shares Down 4.6% After Insider Selling Shares of Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) were down 4.6% on Wednesday after an insider sold shares in the company. The stock traded as low as $112.75 and last traded at $112.72. 74,648 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 548,232 shares. The stock
- 2026-09-23 Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.
- 2026-09-21 BillionToOne SVP Sells 1,416 Shares The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.
- 2026-09-17 BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider''s directly-held equity stake, and a portion belonging to his spouse.
- 2026-09-02 BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.
- 2026-09-01 BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Gross Profit Margin | 68.3% | 53.0% | 24.1% | |
| Ebit Margin | 2.6% | -25.7% | -110.7% | |
| Ebitda Margin | 6.5% | -18.0% | -101.7% | |
| Operating Profit Margin | 5.3% | -30.9% | -96.9% | |
| Pretax Profit Margin | 2.5% | -27.2% | -115.3% | |
| Continuous Operations Profit Margin | 2.4% | -27.2% | -115.3% | |
| Net Profit Margin | 2.4% | -27.2% | -115.3% | |
| Bottom Line Profit Margin | 1.0% | -27.2% | -115.3% | |
| Current Ratio | 11.688 | 8.026 | 1.729 | |
| Quick Ratio | 11.322 | 7.718 | 1.621 | |
| Solvency Ratio | 0.127 | -0.222 | -0.473 | |
| Cash Ratio | 10.341 | 6.745 | 1.456 | |
| Price To Earnings Ratio | 1,284.772 | -117.140 | -58.886 | |
| Price To Earnings Growth Ratio | -12.024 | 2.356 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -12.024 | 2.356 | 0.000 | |
| Price To Earnings Diluted Ratio | 1,284.772 | -117.140 | -58.886 | |
| Price To Earnings Diluted Growth Ratio | -12.024 | 2.356 | 0.000 | |
| Price To Book Ratio | 7.808 | 29.042 | 159.869 | |
| Price To Sales Ratio | 12.286 | 31.929 | 67.920 | |
| Price To Free Cash Flow Ratio | 238.556 | -104.150 | -81.406 | |
| Price To Operating Cash Flow Ratio | 152.416 | -117.748 | -90.771 | |
| Debt To Assets Ratio | 0.172 | 0.362 | 0.764 | |
| Debt To Equity Ratio | 0.227 | 0.652 | 4.802 | |
| Debt To Capital Ratio | 0.185 | 0.395 | 0.828 | |
| Long Term Debt To Capital Ratio | 0.107 | 0.235 | 0.535 | |
| Financial Leverage Ratio | 1.318 | 1.801 | 6.290 | |
| Working Capital Turnover Ratio | 0.857 | 1.230 | 0.000 | |
| Operating Cash Flow Ratio | 0.513 | -1.458 | -0.803 | |
| Operating Cash Flow Sales Ratio | 0.081 | -0.271 | -0.748 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.639 | 1.131 | 1.115 | |
| Debt Service Coverage Ratio | 3.418 | -3.195 | -1.279 | |
| Interest Coverage Ratio | 168.663 | -19.759 | -21.239 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.394 | -6.653 | -0.999 | |
| Operating Cash Flow Coverage Ratio | 0.226 | -0.378 | -0.367 | |
| Capital Expenditure Coverage Ratio | 2.769 | -7.659 | -8.693 | |
| Dividend Paid And Capex Coverage Ratio | 2.769 | -7.659 | -8.693 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 170.112 | -174.382 | -67.466 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 68.3% | ▲15.3% | ▲19.8% |
| Ebit Margin | 2.6% | ▲28.2% | ▲47.2% |
| Ebitda Margin | 6.5% | ▲24.5% | ▲44.2% |
| Operating Profit Margin | 5.2% | ▲36.1% | ▲46.1% |
| Pretax Profit Margin | 2.5% | ▲29.8% | ▲49.2% |
| Continuous Operations Profit Margin | 2.4% | ▲29.7% | ▲49.1% |
| Net Profit Margin | 2.4% | ▲29.7% | ▲49.1% |
| Bottom Line Profit Margin | 1.0% | ▲28.2% | ▲48.1% |
| Current Ratio | 11.688 | ▲3.662 | ▲4.540 |
| Quick Ratio | 11.322 | ▲3.604 | ▲4.435 |
| Solvency Ratio | 0.127 | ▲0.349 | ▲0.316 |
| Cash Ratio | 10.341 | ▲3.595 | ▲4.160 |
| Price To Earnings Ratio | 1284.772 | ▲1401.912 | ▲915.190 |
| Price To Earnings Growth Ratio | -12.024 | ▼-14.380 | ▼-8.801 |
| Forward Price To Earnings Growth Ratio | -12.024 | ▼-14.380 | ▼-8.801 |
| Price To Earnings Diluted Ratio | 1284.772 | ▲1401.912 | ▲915.190 |
| Price To Earnings Diluted Growth Ratio | -12.024 | ▼-14.380 | ▼-8.801 |
| Price To Book Ratio | 7.808 | ▼-21.234 | ▼-57.765 |
| Price To Sales Ratio | 12.286 | ▼-19.643 | ▼-25.092 |
| Price To Free Cash Flow Ratio | 238.555 | ▲342.706 | ▲220.889 |
| Price To Operating Cash Flow Ratio | 152.416 | ▲270.164 | ▲171.117 |
| Debt To Assets Ratio | 0.172 | ▼-0.190 | ▼-0.261 |
| Debt To Equity Ratio | 0.227 | ▼-0.425 | ▼-1.667 |
| Debt To Capital Ratio | 0.185 | ▼-0.210 | ▼-0.284 |
| Long Term Debt To Capital Ratio | 0.106 | ▼-0.128 | ▼-0.185 |
| Financial Leverage Ratio | 1.318 | ▼-0.483 | ▼-1.818 |
| Working Capital Turnover Ratio | 0.857 | ▼-0.373 | ▲0.161 |
| Operating Cash Flow Ratio | 0.513 | ▲1.970 | ▲1.095 |
| Operating Cash Flow Sales Ratio | 0.081 | ▲0.352 | ▲0.394 |
| Free Cash Flow Operating Cash Flow Ratio | 0.639 | ▼-0.492 | ▼-0.323 |
| Debt Service Coverage Ratio | 3.417 | ▲6.613 | ▲3.770 |
| Interest Coverage Ratio | 168.663 | ▲188.423 | ▲126.108 |
| Short Term Operating Cash Flow Coverage Ratio | 4.394 | ▲11.046 | ▲5.480 |
| Operating Cash Flow Coverage Ratio | 0.226 | ▲0.604 | ▲0.399 |
| Capital Expenditure Coverage Ratio | 2.769 | ▲10.429 | ▲7.297 |
| Dividend Paid And Capex Coverage Ratio | 2.769 | ▲10.429 | ▲7.297 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 170.112 | ▲344.493 | ▲194.024 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Market cap | $3.75B | $4.87B | $4.87B | |
| Enterprise value | $3.36B | $4.79B | $4.92B | |
| EV / Sales | 11.02x | 31.39x | 68.60x | |
| EV / Op. cash flow | 136.68x | -115.76x | -91.69x | |
| EV / Free cash flow | 213.92x | -102.39x | -82.23x | |
| EV / EBITDA | 170.11x | -174.38x | -67.47x | |
| Net debt / EBITDA | -19.59x | 2.99x | -0.67x | |
| Current ratio | 11.69x | 8.03x | 1.73x | |
| Income quality | 8.43x | 0.99x | 0.65x | |
| Graham number | $6 | — | — | |
| Graham net-net | $8 | $2 | -$1 | |
| Tax burden | 96.1% | 100.1% | 100.0% | |
| Interest burden | 98.8% | 106.1% | 104.1% | |
| Working capital | $512.6M | $199.4M | $48.7M | |
| Invested capital | $579.7M | $268.3M | $122.6M | |
| Return on assets | 1.2% | -13.8% | -43.1% | |
| Operating ROA | 3.4% | -19.1% | 0.0% | |
| Return on tangible assets | 1.2% | -13.8% | -43.1% | |
| Return on equity | 1.6% | -24.8% | -271.3% | |
| Return on invested capital | 2.6% | -16.8% | -38.9% | |
| Return on capital employed | 2.7% | -17.2% | -55.7% | |
| Earnings yield | 0.2% | -0.9% | -1.7% | |
| Free cash flow yield | 0.4% | -1.0% | -1.2% | |
| Capex / Op. cash flow | 36.1% | -13.1% | -11.5% | |
| Capex / Depreciation | 74.6% | 46.2% | 95.5% | |
| Capex / Sales | 2.9% | 3.5% | 8.6% | |
| SG&A / Sales | 46.9% | 59.9% | 89.8% | |
| R&D / Sales | 16.2% | 24.0% | 31.2% | |
| Stock comp / Sales | 5.2% | 5.5% | 6.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 50d | 59d | 46d | |
| Days payables outstanding | 27d | 22d | 22d | |
| Operating cycle | 116d | 104d | 95d | |
| Cash conversion cycle | 89d | 82d | 73d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years